Cargando…
Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling
Diabetes is a metabolic disease characterized by chronic hyperglycemia. Polygenic diabetes, which encompasses type-1 and type-2 diabetes, is the most prevalent kind of diabetes and is caused by a combination of different genetic and environmental factors, whereas rare phenotype monogenic diabetes is...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199525/ https://www.ncbi.nlm.nih.gov/pubmed/35719247 http://dx.doi.org/10.2147/DMSO.S366967 |
_version_ | 1784727857827676160 |
---|---|
author | Dabi, Yosef Tsegaye Degechisa, Sisay Teka |
author_facet | Dabi, Yosef Tsegaye Degechisa, Sisay Teka |
author_sort | Dabi, Yosef Tsegaye |
collection | PubMed |
description | Diabetes is a metabolic disease characterized by chronic hyperglycemia. Polygenic diabetes, which encompasses type-1 and type-2 diabetes, is the most prevalent kind of diabetes and is caused by a combination of different genetic and environmental factors, whereas rare phenotype monogenic diabetes is caused by a single gene mutation. Monogenic diabetes includes Neonatal diabetes mellitus and Maturity-onset diabetes of the young. The majority of our current knowledge about the pathogenesis of diabetes stems from studies done on animal models. However, the genetic difference between these creatures and humans makes it difficult to mimic human clinical pathophysiology, limiting their value in modeling key aspects of human disease. Human pluripotent stem cell technologies combined with genome editing techniques have been shown to be better alternatives for creating in vitro models that can provide crucial knowledge about disease etiology. This review paper addresses genome editing and human pluripotent stem cell technologies for in vitro monogenic diabetes modeling. |
format | Online Article Text |
id | pubmed-9199525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-91995252022-06-16 Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling Dabi, Yosef Tsegaye Degechisa, Sisay Teka Diabetes Metab Syndr Obes Review Diabetes is a metabolic disease characterized by chronic hyperglycemia. Polygenic diabetes, which encompasses type-1 and type-2 diabetes, is the most prevalent kind of diabetes and is caused by a combination of different genetic and environmental factors, whereas rare phenotype monogenic diabetes is caused by a single gene mutation. Monogenic diabetes includes Neonatal diabetes mellitus and Maturity-onset diabetes of the young. The majority of our current knowledge about the pathogenesis of diabetes stems from studies done on animal models. However, the genetic difference between these creatures and humans makes it difficult to mimic human clinical pathophysiology, limiting their value in modeling key aspects of human disease. Human pluripotent stem cell technologies combined with genome editing techniques have been shown to be better alternatives for creating in vitro models that can provide crucial knowledge about disease etiology. This review paper addresses genome editing and human pluripotent stem cell technologies for in vitro monogenic diabetes modeling. Dove 2022-06-11 /pmc/articles/PMC9199525/ /pubmed/35719247 http://dx.doi.org/10.2147/DMSO.S366967 Text en © 2022 Dabi and Degechisa. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Dabi, Yosef Tsegaye Degechisa, Sisay Teka Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling |
title | Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling |
title_full | Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling |
title_fullStr | Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling |
title_full_unstemmed | Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling |
title_short | Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling |
title_sort | genome editing and human pluripotent stem cell technologies for in vitro monogenic diabetes modeling |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199525/ https://www.ncbi.nlm.nih.gov/pubmed/35719247 http://dx.doi.org/10.2147/DMSO.S366967 |
work_keys_str_mv | AT dabiyoseftsegaye genomeeditingandhumanpluripotentstemcelltechnologiesforinvitromonogenicdiabetesmodeling AT degechisasisayteka genomeeditingandhumanpluripotentstemcelltechnologiesforinvitromonogenicdiabetesmodeling |